Programm

26th of August – Tallinn

 

9:00-11:30Introduction to the week and Estonian Health Tech

  • Getting to know the participants
  • Presentation about e-Health in Estonia
E-Estonia Briefing Centre 

Öpiku maja, Valukoja 8, 11415 Tallinn

11:45-13:30Developing systems, integrations in healthcare and possibilities/use-cases of AI (together with TEHIK)

  • Introduction to the Program Block and an Overview of the Current State of Healthcare Providers’ Information Systems, and Thoughts on the Future Hospital Information System. Presenter: Kertti Merimaa (Nortal)
  • Detailed Introduction to the Health Information System. The presentation answers questions such as what exactly the Health Information System (TIS) is, what value is created by bringing together and sharing TTO data, and what the future thoughts are for upTIS. Presenter: Tõnis Jaagus (TEHIK)
  • Overview of National e-Health Solutions Using the Health Insurance Fund’s Product Portfolio as an Example. The presentation answers questions such as what value national e-health services create in the country, what is offered to Estonian people and TTOs, and how these are connected to national health data exchange. Presenter: Taavi Annus (Health Insurance Fund)
  • Overview of AI Opportunities in Healthcare. The presentation focuses on the possibilities of adopting AI technology in healthcare and the risks associated with AI. Presenter: Elena Sügis (Nortal)
  • Questions for Presenters and Discussion with the Audience
Nortal

Lõõtsa 6, 11415 Tallinn

14:00-17:00Digital health: Current situation, bottlenecks in the system and possibilities for cooperation and growth

  • Presentations by  
    TalTech – Doris Kaljuste, Digital Health MSc Programme Director
    Health Founders – Erki Mölder, Founding Partner
    Tehnopol – Merilin Varsamaa, Head of HealthTech
    Tartu Biotechnology Park – Sven Parkel, CEO
  • Paneeldiskussioon “Bridging the gap between healthcare professionals and tech transformation”.
    Moderator: Kadi Lubi (Senior Researcher and Head – eMed Lab at Department of Health Technologies at TalTech)
    Arutelus osalevad:
    Andres Sutt (Member of the Estonian Parliament)
    Nele Labi (Deputy Secretary GeneralMinistry of Social Affairs)
    Laura Prett (Primary Care Physician at Linnamäe Perearstikeskus)
    Priit Kruus (CEO at Dermtest)
  • Networking
TalTech, Mektory

Raja 15, 12618 Tallinn

17:15Organised bus ride to Tartu 
19:30Arrival in Tartu  

 

27th of August – Tartu

 

9:00-10:30Visit to Estonian Biobank

  • Introduction to the Estonian Biobank and Innovation Centre (Head of Estonian Biobank Innovation Centre, Priit Palta).
  • Introduction to the Science Centre (Head of Estonian Biobank Genome Centre Elin Org)
  • Introduction to the Estonian Biobank (Head of the Biobank Lab, Steven Smit)
Estonian Biobank

Riia 23b, 51010, Tartu

10:45-15:45Visit to Tartu University Hospital

  • Innovation capacity, cooperation models, testbed (Joel Starkopf, Head of Research and Development)
  • Testbed expectations vs reality (Rainis Kolga, Head of Digital Services; Richard Jalakas, Project Manager at Digital Services)
  • Lunch at the cafeteria
  • Practical examples
    – Antegenes  (https://antegenes.com) – Peeter Padrk (CEO / Oncologist)
    – EsaDres (https://www.esadres.com/) – Karin Kogermann (CEO and Co-Founder)
  • Tour and showcasing the newest innovations
  • Icosagen – pioneering biotechnology and drug development

Icosagen stands as a premier Estonian biotechnology and drug development enterprise. Renowned for its scientific excellence, high-growth trajectory and knowledge-intensive approach. Icosagen operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), pioneering novel technologies and offering antibody identification and protein production services to the pharmaceutical and biotechnology sectors. 

Tartu University Hospital

Ludvig Puusepa 8, 50406 Tartu

16:00-17:00Visit to Icosagen
(organised bus ride from Tartu University Hospital to Icosagen)
Icosagen
Eerika tee 1, Õssu, 61713 Tartu maakond
17:30Networking / Community meetup – EstBAN Tartu x DeepTech Pub – Health edition

This meetup brings us together to foster connections among investors, Healthtech, Biotech, Deep tech startups, and community builders across Estonia as well as guests of Estonian Health Tech Week. The event is co-hosted by Startup Estonia, EstBAN, Tartu Biotechnology Park and Sparkup Tartu Science Park as a joint meetup during Estonian Health Tech Week.

Register here 

Restoran Humal, Riia 4, 51004 Tartu

 

28th of August – Tartu

DTx New Nordics conference https://dtxnewnordics.com

Kammivabriku sündmuskeskus, Teguri 26, 50107 Tartu

29th of August – Tartu

 

10:00-10:30ScanBalt/EDAH seminar: Creating Value Through Health Data

  • Welcome and setting the scene
  • Introduction from UniTartu Ventures
  • Introduction from Estonian Multiomics Company (EMC)
VSpa Hotel Conference Centre (Riia 2, 51004 Tartu)
10:30-12:00Including data donors in the value generation flow

Moderator: Maciej Drozdz, founder of SpringLab.tech

Kristjan Vassil, Chair of the supervisory board, Tartu University Hospitals/ Former vice rector of research Tartu University

Mart Maasik, CEO of UniTartu Ventures

Kaarel Krjutskov, Associate Professor in Molecular Medicine, Tartu University/Competence Centre on Health Technologies

Progress in discovering biological processes that can be addressed by pharmacological intervention (or other therapeutic methods) is dependent on wide access to human biological material and information. The patient consent agreement is the basic legal agreement between the donor and the biobank and the ultimate user of the patient biomaterial or data resulting from it. There is a conflict of interest between the owner of the biological material and the user. The current legal and technical framework does not allow patients (or biobanks on patients’ behalf) to dynamically adjust (grant or withdraw) permits for a unit of information or biomaterial. The potential value of information contained in biological material is enormous and can lead to key observations that for example to the discovery of molecules that will become drugs and thus generate substantial revenue. At the same time, the current modus operandi/business model of biobanks is based on the voluntary, altruistic behaviour of people who, under certain conditions, agree to make their biological material available to the biobank collection. Is this controversy solvable? The session is aimed to discuss whether and how we can use modern methods of information management (e.g. blockchain/NFT/AI) in generating an economic model and information technology tools to include donors of biological material in the flow of value generated through the use of their material while enabling users of this material a necessary level of access.

 
12:00-12:45Lunch
12:45-14:15Secondary use of health data and IP rights in the EHDS

Moderator: Elina Drakvik, Senior Lead at Sitra (Finnish Innovation Fund)

Guillaume Byk. Legislative and Policy Officer, European Commission, DG SANTE 

Aneta Tyszkiewicz, Director Digital and Data, European Federation of Pharmaceutical Industries and Associations

Katrine Højen Vad, Head of Section, Danish Health Data Authority

Michel Silvestry, Head of Unit, The Swedish eHealth Agency 

 

The session will focus on discussing how the European Health Data Space (EHDS) should be implemented optimally, promoting access to data and boosting research and innovation while also addressing IP rights, including trade secrets, through necessary measures to preserve confidentiality when sharing data for secondary use. The EHDS text specifically stipulates that electronic health data containing protected IP and trade secrets should be made available for secondary use but with necessary measures to preserve confidentiality, prescribing this role to Health Data Access Bodies (HDABs). Furthermore, the text stipulates that if measures are deemed to be insufficient to ensure the protection of IP rights or the confidentiality of the data, the HDAB shall refuse the granting of the relevant health data access permit to the health Data User. Practical measures and tools will be needed for HDABs on how to safeguard IP rights, as these rights have effectively fuelled the transformative development and advancements in healthcare and medicine until now. The session will take a deep dive into the subject matter through short presentations and a panel discussion bringing up the views of industry, a Member State and HDAB and discussing first ideas on how to move forward in this complex area in a constructive manner.

 
14:15-14:30Coffee break
14:30-16:00The potential of AI for the early diagnosis of Alzheimer’s – research, law and political standardization

Moderator: Oliver Stenzel, Head of Digital Health Working group at ScanBalt

Doreen Goerss, Rostock University Medical Center

Ella Kadas, CEO at Nocturne

Paula Salme Sandrak, Interdisciplinary Product Strategist in Health AI & Biotech in Noncommunicable Chronic Diseases at Bayer

Ain Aaviksoo, Head of Development and Partner at Heba

Nicklas Linz, Co-founder & CEO at ki elements

Holger Froelich, Head of AI & Data Science at Fraunhofer SCAI; Professor at University of Bonn

Eduard Maron, CEO at DocuMental Visiting professor, Imperial College London 

Artificial intelligence can be a blessing for the medicine of the future. We can use it for the development of new therapies as well as for the early diagnosis of diseases or the long-term care of patients. Personalized medicine in particular needs the ability to analyze large volumes of data and develop tailored solutions. But there are also high hopes for AI in complex widespread diseases such as Alzheimer’s disease – in particular, a timely diagnosis should be made easier and faster by analyzing and linking a wide range of everyday parameters. For some, this is a blessing, while others see it more as a threat. To fulfil the expectations placed on it, AI must penetrate deep into the reality of our lives – appropriate legal and political regulation is just as necessary as a broad ethical discourse. In our session, we will approach this complex topic from different angles.

 

 

Community partners